Uniocular Anterior Chamber Inoculation of a Tumor Necrosis Factor Alpha-Expressing Recombinant of Herpes Simplex Virus Type 1 Results in More Rapid Destruction and Increased Viral Replication in the Retina of the Uninoculated Eye

Department of Cellular Biology and Anatomy, Medical College of Georgia, Augusta, GA 30912, USA.
Journal of Virology (Impact Factor: 4.44). 06/2008; 82(10):5068-78. DOI: 10.1128/JVI.00082-08
Source: PubMed


Tumor necrosis factor alpha (TNF-α) has been shown to have a protective role in the eyes and brains of herpes simplex virus
type 1 (HSV-1)-infected mice. To determine whether overexpression of TNF-α affected the course of virus infection following
uniocular anterior chamber inoculation, a recombinant of HSV-1 that produces TNF-α constitutively (KOSTNF) was constructed. BALB/c mice were injected with the TNF-α recombinant, a recombinant containing the pCI plasmid, a recombinant
rescue virus, or the parental virus. Flow cytometry and immunohistochemistry were used to identify virus-infected cells and
to determine the numbers and types of infiltrating inflammatory cells in the uninjected eyes. Virus titers were determined
by plaque assay. There were no differences among the groups in virus titers or the route and timing of virus spread in the
injected eyes or in the suprachiasmatic nuclei. However, in the uninjected eyes of KOSTNF-infected mice, TNF-α expression was increased and there were more viral antigen-positive cells and immune inflammatory cells.
There was earlier microscopic evidence of retinal infection and destruction in these mice, and the titers of virus in the
uninjected eyes were significantly increased in KOSTNF-infected mice on day 7 postinfection compared with those of KOSpCI-, KOS6βrescue-, or KOS6β-infected mice. The results suggest that instead of moderating infection and reducing virus spread, overexpression of TNF-α
has deleterious effects due to increased inflammation and virus infection that result in earlier destruction of the retina
of the uninoculated eye.

Download full-text


Available from: Sally S Atherton, Jan 15, 2015
  • Source
    • "TNF-a also produced a significant benefit when administered up to 8 h after the infection in a lethal mouse model of HSE (Rossol-Voth et al., 1991). However, an over-expression of TNF-a constitutively produced by a recombinant HSV-1 strain inoculated in the eye had deleterious effects due to increased inflammation and viral replication (Fields et al., 2008). High levels of TNF-a were also shown to induce blood–brain barrier (BBB) disruption (Candelario-Jalil et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The added benefit of combining valacyclovir (VACV), an antiviral agent, with etanercept (ETA), an anti-tumor necrosis factor alpha (TNF-α) antibody, for the treatment of herpes simplex virus type 1 (HSV-1) encephalitis (HSE) was evaluated in a mouse model. BALB/c mice were infected intranasally with 1.85 × 104 plaque forming units of HSV-1. Groups of mice received a single intraperitoneal injection of vehicle or ETA (400 μg/mouse) on day 3 post-infection combined or not with VACV (1 mg/ml of drinking water) from days 3 to 21 post-infection. On day 5 post-infection, groups of mice were sacrificed for determination of viral DNA load, detection of ETA in brain homogenates and for in situ hybridization. The survival rate of mice was significantly increased when VACV was administered in combination with ETA (38.5% for VACV vs 78.6% for combined treatment; P = 0.04) although VACV or ETA alone had no significant effect compared to the vehicle. The benefit of combined therapy was still present when treatment was delayed until day 4 post-infection. The viral DNA load was significantly reduced in mice treated with VACV alone (P < 0.01) or combined with ETA (P < 0.05) compared to the uninfected group whereas ETA alone had no effect. These results reinforce the notion that both virus-induced and immune-related mechanisms participate in the pathogenesis of HSE and suggest that potent antiviral agent could be combined with immune-based therapy, such as a TNF-α inhibitor, to improve prognosis of HSE.
    Full-text · Article · Dec 2013 · Antiviral research
  • [Show abstract] [Hide abstract]
    ABSTRACT: Herpes simplex virus-type 2 (HSV-2) can cause acute retinal necrosis (ARN), which can lead to exudative and rhegmatogenous retinal detachment, yet little is known about the cellular and molecular mechanisms of HSV-2 entry into retinal pigment epithelial (RPE) cells. The goal of this study was to establish the identity of the critical receptors used by the virus for infection. A reporter HSV-2 virus, which expresses beta-galactosidase, was used to quantify entry into RPE cells, and viral replication was ascertained using a plaque assay. Flow cytometry and immunocytochemistry were used to determine cellular expression of entry receptors. Localization of these receptors to the apical or basal surface of RPE cells was determined with immunocytochemistry. The necessity of these receptors, individually and in combination, for viral entry was established using receptor-specific antibodies and siRNAs. RPE cells are highly susceptible to HSV-2 entry and replication. Several assays demonstrated the expression of the entry receptors nectin-1, HVEM, and PILR-alpha and their localization primarily to the apical surfaces of RPE cells. Receptor-specific antibodies and siRNA knockdown of receptors significantly reduced viral entry and implicated nectin-1 as an important receptor, with HVEM and PILR-alpha potentially also contributing to entry. HSV-2 is capable of developing a productive infection in RPE cells by using nectin-1 as an important entry receptor. To lesser degrees, HVEM and PILR-alpha may also contribute to HSV-2 entry into RPE cells.
    No preview · Article · Mar 2009 · Investigative ophthalmology & visual science